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ABSTRACT
Introduction Ceftaroline, tedizolid, dalbavancin, 
ceftazidime- avibactam and ceftolozane- tazobactam 
are novel antibiotics used to treat infections caused by 
multidrug- resistant pathogens (MDR). Their use should 
be supervised and monitored as part of an antimicrobial 
stewardship programme (ASP). Appropriate use of the 
new antibiotics will be improved by including consensual 
indications for their use in local antibiotic guidelines, 
together with educational interventions providing advice 
to prescribers to ensure that the recommendations are 
clearly understood.
Methods and analysis This study will be implemented 
in two phases. First, a preliminary historical cohort 
(2017–2019) of patients from 13 Andalusian hospitals 
treated with novel antibiotics will be analysed. Second, a 
quasiexperimental intervention study will be developed 
with an interrupted time- series analysis (2020–2021). 
The intervention will consist of an educational interview 
between prescribers and ASP leaders at each hospital 
to reinforce the proper use of novel antibiotics. The 
educational intervention will be based on a consensus 
guideline designed and disseminated by leaders after 
the retrospective cohort data have been analysed. The 
outcomes will be acceptance of the intervention and 
appropriateness of prescription. Incidence of infection and 
colonisation with MDR organisms as well as incidence 
of Clostridioides difficile infection will also be analysed. 
Changes in prescription quality between periods and the 
safety profile of the antibiotics in terms of mortality rate 
and readmissions will also be measured.
Ethics and dissemination Ethical approval will be 
obtained from the Andalusian Coordinating Institutional 
Review Board. The study is being conducted in compliance 
with the protocol and regulatory requirements consistent 
with International Council of Harmonisation E6 Good 
Clinical Practice and the ethical principles of the latest 
version of the Declaration of Helsinki. The results will be 
published in peer- reviewed journals and disseminated at 
national and international conferences.
Trial registration number NCT03941951; Pre-results.
INTRODUCTION
In the last decade, the rate of infections 
caused by multidrug- resistant (MDR) 
pathogens has increased, together with the 
morbidity, mortality and costs associated 
with them. Indeed, antimicrobial resistance 
is considered today to be one of the most 
important public health problems world-
wide.1 2 The WHO has developed a list of the 
priority organisms to guide research, as well 
as guidelines to encourage surveillance and 
the development of therapeutic strategies for 
treatment of MDR infections.3 Based on these 
criteria, the following pathogens have been 
established as of critical priority: carbapenem- 
resistant Acinetobacter baumannii and Pseudo-
monas aeruginosa; Enterobacterales resistant to 
carbapenems and third- generation cepha-
losporins; vancomycin- resistant Enterococcus 
faecium (VREf); and methicillin- resistant 
Staphylococcus aureus (MRSA). Against this 
background, the WHO is urging the inter-
national community to develop strategies to 
Strengths and limitations of this study
 ► This study will implement an educational interven-
tion by using a consensus guideline.
 ► A Delphi methodology survey will be used for the 
creation of the consensus guideline.
 ► This approach is useful for controlling the prescrip-
tion of antibiotics by exploring the relation between 
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prevent infection and optimise management of infections 
caused by these organisms by developing programmes to 
optimise antimicrobial use (antimicrobial stewardship 
programmes) and promoting the development of new 
molecules to treat these infections.4–6
Treatment of infections caused by Enterobacterales resis-
tant to third- generation cephalosporins has been based 
on carbapenems, and infections caused by carbapenem- 
resistant gram- negative bacteria on colistin- based regi-
mens, frequently in combination with another active 
antibiotic such as an aminoglycoside, tigecycline, fosfo-
mycin or carbapenems (if the MIC is low enough to be 
achieved by optimised dosing schemes).7 8 With respect 
to VREf and MRSA, treatment has pivoted around glyco-
peptides, linezolid and daptomycin.9 In the last few years, 
some new antibiotics have been introduced to the market. 
The novel antibiotics have specific indications approved 
by regulatory organisations, mostly based on the results of 
pivotal clinical trials (table 1). However, there is medical 
necessity in the treatment of other infections caused by 
MDR organisms and in these cases, novel antibiotics are 
frequently used ‘off- label’. Some examples are the use 
of ceftaroline for endocarditis,10 11 tedizolid for osteo-
myelitis12 and ceftolozane/tazobactam for pneumonia,13 
intravascular infections14 or patients with cystic fibrosis.15 
This type of use may lead to improved outcomes in 
patients when they are really needed, but also to increased 
rates of unexpected adverse events, faster development 
of resistance and higher acquisition costs. The risk of 
fast development of resistance to last- resort antibiotics 
against extensively- drug resistant (XDR) pathogens such 
as carbapenem- resistant gram negatives is particularly 
worrying.16 17 Off- label use of antibiotics in general is 
known to be common,18 and increases when antimicro-
bial resistance is more prevalent.19 Consequently, off- label 
use of the new antibiotics is expected to be particularly 
high in settings where MDR pathogens are endemic, 
although to the best of our knowledge, the frequency and 
reasons for this have not so far been assessed. Antimicro-
bial stewardship programmes should therefore prioritise 
actions promoting appropriate use of the new antibiotics, 
which could lead to decreased antimicrobial resistance as 
well as improved patient outcomes.20 21
With the above considerations in mind, the aims of 
this study are to characterise the use of the new antibi-
otics in different Spanish hospitals in order to propose 
a consensus guideline for their use, and to implement a 
non- compulsory antimicrobial stewardship (AMS) inter-
vention to facilitate adherence to the recommendations.
STUDY OBJECTIVES
The primary objective of the study will be to assess the 
impact of an AMS educational intervention on physi-
cians prescribing some of the novel antibiotics available 
for MDR infections. The corresponding outcomes will be 
acceptance of the intervention and appropriateness of 
prescriptions.
Secondary objectives will include: (1) creation of a 
cohort of patients with complex infections caused by 
MDR microorganisms22 treated with any of the novel 
antimicrobials; (2) to carry out a descriptive analysis 
Table 1 Target antibiotics for the study
Antibiotic Activity (multidrug- resistant pathogen) Indications approved (agency)




Tedizolid MRSA, VRE ABSSSI (EMA, FDA)
Dalvabancin MRSA, VRE ABSSSI (EMA, FDA)
Oritavancin MRSA, VRE ABSSSI (EMA, FDA)
Delafloxacin MRSA ABSSSI (FDA)
Ceftolozane- tazobactam ESBL and AmpC- producing Enterobacterales 
and P. aeruginosa
cIAI, cUTI (EMA, FDA)
Ceftazidime- avibactam ESBL, AmpC, KPC, OXA-48- producing 
Enterobacterales and P. aeruginosa
cIAI, cUTI (EMA; FDA)
HAP/VAP (EMA)
Meropenem- vaborbactam ESBL, AmpC, KPC- producing 
Enterobacterales and P. aeruginosa
cUTI (EMA, FDA) cIAI, HAP/VAP, gram 
negatives with limited options (EMA)
Imipenem- relebactam ESBL, AmpC, KPC- producing 
Enterobacterales and P. aeruginosa
cUTI, cIAI with limited options (FDA)
Eravacycline Enterobacterales* cIAI (EMA, FDA)
Plazomicin Enterobacterales, P. aeruginosa* cUTI with limited options (FDA)
*Not affected by beta- lactamases.
ABSSSI, acute bacterial skin and skin structure infections; CABP, community- acquired bacterial pneumonia; cIAI, complicated intra- 
abdominal infections; cUTI, complicated urinary tract infections; EMA, European Medicines Agency; ESBL, extended- spectrum beta- 
lactamases; FDA, Food and Drug Administration; HAP, hospital- acquired pneumonia; KPC, Klebsiella pneumoniae carbapenemase; MRSA, 
methicillin- resistant Staphylococcus aureus; VAP, ventilator- associated pneumonia; VRE, vancomycin- resistant Enterococcus spp.
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(epidemiological, clinical and prognosis) of the retro-
spective cohort; (3) to develop an Andalusian consensus 
document for the correct use of the novel antimicrobials, 
with particular focus on indications that exceed the offi-
cially approved ones; (4) to evaluate variables predicting 
mortality in a cohort of patients treated with the new anti-
biotics; (5) to evaluate the impact on the development 
of resistance of an AMS intervention on prescriptions of 
novel antibiotics; and (6) to analyse the safety of the use 
of novel antibiotics in a cohort of patients with bacter-
aemia caused by MDR and XDR organisms. The outcomes 
corresponding to these objectives are stated in table 2.
METHODS AND ANALYSIS
The Standard Protocol Items: Recommendations forInt-
erventional Trials statement will be followed in order to 
standardise the trial23 (see online supplementary table 
S1).
Study design, setting and study period
This project is conceived as a multicentre registry for 
target antibacterial antibiotics that have been commer-
cially available in Spain since 2016, including ceftaro-
line, tedizolid, dalbavancin, ceftolozane- tazobactam and 
ceftazidime- avibactam; other antibiotics commercialised 
during the study period will be added. It is designed as 
an ambispective cohort study with a retrospective phase, 
including all prescriptions between January 2016 and 
December 2019, and a prospective phase, from January 
2020 to December 2021. A time series analysis of monthly 
consumption data, measured as defined daily dose 
(DDD) per 1000 patient days, will enable exploration of 
the impact of the AMS intervention aimed at improving 
antibiotic use (see online supplementary table S2).
A ‘safety cohort’ of patients diagnosed with blood-
stream infection (BSI) caused by MDR organisms (see 
below) during the study period and not treated with the 
target antibiotics will also be recruited. This safety cohort 
will be used as a comparator, in terms of safety and clin-
ical outcomes, for patients in the target antibiotics cohort 
with BSIs caused by the same organisms (see below).
Thirteen tertiary public hospitals located in the region 
of Andalucía (Spain) will participate. All hospitals have 
active AMS programmes.
Patients
Patients will be included in the registry if any of the target 
antibiotics are prescribed in the corresponding study 
periods. Participants will be detected through the elec-
tronic prescribing systems at each hospital. There are no 
exclusion criteria.
Patients in the safety cohort will include all patients with 
BSI caused by carbapenem- resistant Enterobacterales 
and P. aeruginosa, MRSA or vancomycin- resistant Entero-
cocci not treated with any of the target antibiotics. For the 
comparison, these patients will be compared with those 
in the registry with BSIs caused by the same organisms. 
Table 2 Variables to be collected during the whole of the 
study period
Patient characteristics Hospital, age, gender
  Chronic underlying conditions*
  Charlson Comorbidity Index
  Immunosuppressant antibiotics 
(past 3 months)
  Surgery (past month)
  Vascular catheter (past week)
  Urinary catheter (past week)
  Mechanical ventilation (past 
week)
  Pitt score
  Creatinine clearance, renal 
replacement therapy
Infection related Acquisition type (community- 
acquired, community- onset 
but healthcare- associated,† 
nosocomial)
  Site of infection‡
  Presentation with sepsis or 
septic shock§
  Causative microorganism(s)
  Susceptibility
  Presence of bacteraemia
Prescription and 
management related
Antibiotic(s), start date, 
discontinuation date
  Dose, route
  Type of indication: prophylaxis, 
empirical, definitive
  Reasons for discontinuation: 
end of treatment, clinical 
failure, microbiological failure, 
adverse event, de- escalation, 
switch to oral, switch to a 
more convenient antibiotic for 
outpatient use, death
  Total defined daily doses
  Total antibiotic cost
  Source control
  Fluid resuscitation, amines 
administration
Secondary outcomes Clinical and microbiological 
cure¶
  Development of resistance 
during treatment
  Recurrence, superinfection 
(until day 30)
  Length of hospital stay
  Adverse events (including 
Clostridioides difficile infection 
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The exclusion criteria in this analysis include polymi-
crobial BSIs, death in <48 hours after initiation of active 
therapy or lack of treatment with at least one active antibi-
otic in the first 4 days after the blood cultures were taken. 
In order to avoid survivor bias, patients in the registry will 
only be included if the antibiotic of interest was started in 
the first 3 days after the blood culture was taken.
Variables and data collection
The variables to be collected are shown in table 2. 
The main endpoints for the registry study will include 
monthly pooled and hospital- specific DDD of the target 
antibiotics18 per 1000 patient days; appropriateness of the 
prescription according to local protocol and consensus 
document (see definitions in table 2); rate of clinical and 
microbiological cure; rate of adverse events (including 
Clostridioides difficile infection); and mortality. The main 
endpoint for the comparative analysis in patients with 
bacteraemia will be 30- day mortality. Secondary outcomes 
will include length of stay and rate of severe adverse 
events.
The evaluation of the quality of prescriptions and 
outcomes will be assessed by one local and one external 
investigator. Discrepancies will be resolved by a third, 
external investigator. The data will be collected from elec-
tronic charts and entered into a secure electronic case 
report form.
Intervention
The intervention will be performed from January 2020 
and will include: (1) development of a consensus docu-
ment by a panel comprising one investigator per site with 
recommendations for the use of the target antibiotics. 
The recommendations will be based on data obtained 
in the retrospective part of the registry and a review of 
the literature. Because high- level evidence is expected 
to be lacking for the purposes of stewardship consid-
erations, consensus will be achieved using the Delphi 
methodology, with three rounds of responses. The 
questions to be provided to the panel will be designed 
taking into account the clinical relevance of the deci-
sions, the ecological impact, the costs of the antibiotics 
and the results obtained from the historical cohort; (2) 
the consensus document will be disseminated among 
participating hospitals using the channels provided by 
the public healthcare system and the Andalusian Society 
of Infectious Diseases, as well as the social media; (3) for 
each prescription, a prescribing audit will be undertaken 
with advice to prescribers. The audit will be performed 
in the first 24 hours after a prescription is made and will 
consist of a brief meeting (around 10 min) between a 
member of the AMS team (also a study subinvestigator) 
and the prescriber, and will be based on a semistructured 
interview aimed at evaluating the prescription according 
to the consensus document, followed by non- compulsory 
advice to modify the prescription when needed.
Timeline
Figure 1 shows the timeline of the study. The first 6 
months are planned for start- up activities. The first 
analyses will take place at the beginning of 2020. The 
consensus guideline will be developed between January 
and September 2020. The final analysis is planned for 
October–December 2021. The safety cohort will collect 
information from 2017 to 2021. Inclusion and exclusion 
criteria of each cohort are included in box 1.
Patient characteristics Hospital, age, gender
  30- day mortality
Prescriber Medical specialty
  Position
Evaluation/audit Quality of prescription 
according to local protocol: 
fully appropriate, inappropriate 
(reasons: indication, route, 
dosing, duration), unnecessary.
  Quality of prescription 
according to consensus 
recommendations: fully 
appropriate, inappropriate 
(reasons: indication, route, 
dosing, duration), unnecessary 
(primary outcome).
  Off- label use (EMA label)
  Audit performed/not performed
  If audit performed, 
recommendation: none, 
discontinue, specific duration, 
change in dosing
  Adherence to recommendation: 
full/partial/none (primary 
outcome)
Classification of treatment Empirical/definitive
Type of infection/indication Site of infection
Presence of bacteraemia





Dosing (Specify if adjusted according 
to renal function)
Start and discontinuation 
dates
  
Reason(s) for using the 
antibiotic specified in the 
chart
Failure of previous treatment
Isolation of MDR pathogen
*According to chart.
†Acute or long- term care facility admission, invasive procedure or 
intravenous ambulatory therapy in the last 3 months.
‡According to standard clinical and microbiological criteria.
§Third International Consensus Definitions for Sepsis and Septic 
Shock (Sepsis-3).
¶Clinical cure: resolution of all new signs and symptoms related to 
the infection. Microbiological cure: negative follow- up cultures.
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Sample size calculation
Between 2016 and 2018, a survey of the use of the target 
antibiotics was conducted in participating hospitals. 
Overall, 83 prescriptions of ceftazidime/avibactam, 55 
of ceftolozane/tazobactam, 5 of ceftaroline, 43 of dalba-
vancin and 4 of tedizolid were reported. On the basis of 
these results and the increase in prescriptions from 2019, 
400 prescriptions will be included in the registry. In the 
intervention cohort, we will include 200 patients, which 
will allow us to plot trends and perform time series anal-
yses. We estimate that 300 episodes of BSIs caused by MDR 
pathogens will be included in the safety cohort. Estimated 
mortality is around 35%,24 allowing 4–5 confounders to 
be included in the mortality model.
Statistical analysis
Frequencies and percentages of categorical variables will 
be calculated, with median and IQRs for continuous vari-
ables. Trends in bimonthly data of DDDs per 1000 patient 
days (72 measurements) will be evaluated by time series 
using autoregressive integrated moving average (ARIMA) 
models (24 measurements after the start of the inter-
vention). The effect of the intervention and potential 
confounders will be analysed.
An exploratory comparison of the impact of the inter-
vention on the proportion of appropriate prescriptions 
before and after the intervention will be performed 
by logistic regression models, including possible 
confounders (patient and infection- related characteris-
tics) if potentially associated with the prescription, with 
different distributions in the before and after periods 
(p<0.2); for comparisons, the Student’s t- test or Mann- 
Whitney U test will be performed for continuous variables 
with normal and non- normal distributions, and the χ2 or 
Fisher’s test for categorical variables, respectively.
Clinical outcomes between bacteraemic patients treated 
with target antibiotics and the control group of patients 
with MDR bacteraemia will be compared using linear, 
logistic or Cox regression, as appropriate. A propensity 
Figure 1 Timeline of NEW_SAFE project.




 ► All patients treated with ceftaroline, tedizolid, dalbavancin, 
ceftazidime- avibactam and ceftolozano- tazobactam
 ► Either as an outpatient or hospitalised
 ► Receiving at least 1 dose of antibiotic, either as empirical or targeted 
treatment
 ► ≥18 years old
 ► From January 2016 to December 2019
Exclusion criteria
 ► There are not exclusion criteria
Prospective/intervention cohort
Inclusion criteria
 ► All patients treated with ceftaroline, tedizolid, dalbavancin, 
ceftazidime- avibactam and ceftolozano- tazobactam
 ► Either as an outpatient or hospitalised
 ► Receiving at least 1 dose of antibiotic, either as empirical or targeted 
treatment
 ► ≥18 years old
 ► From January 2020 to December 2021
 ► Since spread of guideline with recommendations regarding the use 
of antibiotics
Exclusion criteria
 ► There are not exclusion criteria
Safety cohort
Inclusion criteria
 ► All episodes of clinically significant bacteraemia which have re-
ceived any antibiotic due to: Acinetobacter baumannii resistant/
intermediate susceptibility to any carbapenem; Pseudomonas aeru-
ginosa resistant to ceftazidime and resistant/intermediate suscep-
tibility to any carbapenem; Enterobacterales resistant/intermediate 
susceptibility to any carbapenem, Enterococcus faecium resistant 
to vancomycin and Staphylococcus aureus resistant to methicillin
 ► From January 2017 to December 2021
 ► ≥18 years old
Exclusion criteria
 ► There are not exclusion criteria
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score for use of target antibiotics will be calculated and 
used as covariate and matching variable. The final model 
will be adjusted by centre and comorbidities.
The analyses will be performed using IBM SPSS statis-
tical software.
Patient and public involvement
Neither patients nor public authorities have been involved 
in the development of this study protocol.
ETHICS AND DISSEMINATION
The study is funded by the Consejería de Salud, Junta 
de Andalucía (Regional Government of Andalusia). It 
has been authorised by the Spanish Regulatory Agency 
(Agencia Española del Medicamento y Productos Sani-
tarios) and approved by the Andalusian Coordinating 
Institutional Review Board (CCEIBA), which waived the 
need to obtain written informed consent as the inter-
vention will be performed as a quality improvement 
programme. In addition, contracts were signed by the 
management director of the hospitals. All data will be 
anonymised. The study will be conducted in compli-
ance with the protocol and regulatory requirements 
consistent with International Council of Harmonization 
(ICH) E6 Good Clinical Practice and the ethical princi-
ples of the latest version of the Declaration of Helsinki 
adopted by the World Medical Association. The relevant 
ethics committee(s) will be notified of each substantial 
protocol amendment for approval prior to implementa-
tion. All data collected will be kept strictly confidential 
and in accordance with all relevant legislation on the 
control and protection of personal information. Partic-
ipants will be identified on documentation by a unique 
ID number, not by name, in accordance with the Euro-
pean Regulation on data protection (EU 2016/679). All 
study- related information will be stored securely at the 
study sites.
Dissemination policy: final results will be publicly 
disseminated, regardless of the study outcomes. The 
results of this study will be published in peer- reviewed 
journals, as well as at national and international confer-
ences. All participating hospitals agree with the dissemi-
nation policy.
DISCUSSION
The aims of this study will be to characterise the prescrip-
tions of the newly commercialised antibacterial agents and 
to evaluate the impact of a non- compulsory intervention 
on prescribers. It is expected that these antibiotics will be 
frequently prescribed off- label10–15 and based on hetero-
geneous criteria because they first became commercially 
available when there was medical necessity but very little 
evidence and experience of the potential benefits and 
consequences of their use. Our proposal therefore is to 
develop a guidance document, which will be the basic tool 
of the intervention, to help prescribers in their decision- 
making. We will also explore the outcomes of patients 
treated with these antibiotics in terms of mortality, failure, 
length of hospital stay, development of resistance and C. 
difficile infection.
New antibiotics are particularly welcome in the present 
situation because there is a real medical necessity for anti-
biotics active against some MDR bacteria (and a limited 
number of antibiotics in the pipeline).3 However, new 
antibiotics should always be used prudently, for three 
reasons: first, some adverse events may have gone unde-
tected in the pivotal trial; second, their efficacy may have 
been overestimated if higher risk patients were under- 
represented in trials; and third, specifically in the case 
of antibiotics, the development and spread of resistance 
pose a very real threat. It is very important therefore to 
develop specific AMS interventions aimed at facilitating 
appropriate antibiotic use. The task of the stewardship 
team is to minimise barriers to use in situations where 
they can be beneficial, while at the same time helping 
avoid overuse.
Pharmaceutical companies have frequently promoted 
the development of registries to evaluate the efficacy and 
safety of their products. However, we think such studies 
would be better performed by independent academic 
investigators to avoid the conflicts of interest typical of 
industry- promoted phase 4 studies. To the best of our 
knowledge, this will be the first project aiming to charac-
terise the use of all the newer antimicrobials and to eval-
uate an intervention on their use.
We conceive this project as a registry to provide infor-
mation about the use of the target antibiotics and as an 
AMS intervention. In the field of infection control and 
ASM, quasiexperimental designs have been widely used.25 
Recommendations for designing studies to evaluate AMS 
interventions have recently been published.26 A quasi-
experimental design can provide an estimation of the 
impact of specific interventions and is used when rando-
misation is not feasible for ethical or logistical reasons. 
However, a quasiexperimental study has limitations. With 
respect to the methodology of the intervention, peer- to- 
peer interviews between prescribers and advisors have 
been shown to be effective for reducing consumption of 
antimicrobials.27 28
The study has some obvious limitations, such as lack 
of randomisation; we will try to control for the effect of 
confounders in multivariate analysis. Second, since the 
epidemiology may differ from site to site, the effect of the 
site will also be considered. Third, the recommendations 
provided by the AMS experts may be heterogeneous; 
to control for that possibility, the consensus document 
on the use of new antibiotics will be useful to help stan-
dardise the recommendations. The strengths of the study 
include its multicentre design and the inclusion of sites 
with active AMS programmes.
In conclusion, our study will evaluate the use of new 
antibiotics and evaluate an AMS intervention to opti-
mise their use. We hope the findings will help improve 
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antimicrobial prescriptions and save the activity of novel 
antibiotics for future multiresistant infections.
TRIAL STATUS
Current protocol approved is V.1.1, dated 11 July 2019.
Dates of recruitment for the retrospective cohort: 
started 1 June 2019 and finished on 31 December 2019; 
and for the intervention cohort, 1 April to 30 September 
2021.
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